• Biomolecules & Therapeutics
• /
• 제2권1호
• /
• pp.77-81
• /
• 1994

The acute toxicity of recombinant human epidermal growth factor, DWP-401 was evaluated in ICR mice of both sexes. Six groups of mice were administered orally or subcutaneously with 0, 0.125, 0.25, 0.5, 1 and 2 mg/kg of DWP-401. Abnormal clinical signs related to the compound were not observed, and no deaths occurred. Gross findings of necropsy revealed no evidence of specific toxicity related to DWP-401. LD$_{50}$ values for both male and female mice were evaluated to be over 2 mg/kg, which is approximately 2, 000 fold of presumed clinical dose.e.

• 한국식품위생안전성학회지
• /
• 제9권1호
• /
• pp.31-36
• /
• 1994

The acute toxicity of recombinant human epidermal growth factor, DWP-401 was evaluated in SD rats. Male and female rats aging 6 weeks were administered orally or subcutaneously with 0, 0.125, 0.25, 0.5, 1 and 2 mg/kg of DWP-401. No deaths and no toxic symptoms related to the DWP-401 were observed. The body weights of treated animals were not significantly different from the controls. The results of necropsy revealed no abnormal gross findings of the organs in treated animals. LD50 values of DWP-401 for male and female rats were estimated to be over 2 mg/kg, which is approximately 2, 000 times of expected clinical dose.

• Biomolecules & Therapeutics
• /
• 제4권2호
• /
• pp.138-147
• /
• 1996

DWP401, a recombinant human epidermal growth factor, was subcutaneously administered to ICR mice at the dose levels of 0, 0.04, 0.2 and 1.0 mg/kg/day (15rats/sex/group) in order to evaluate the subchronic toxicity. General observations, examinations for food and water consumption, ophthalmoscopy and urinalysis were carried out during the study. For the complete gross and microscopic examinations, 10 mice/ sex/group were sacrificed at the ends of the dosing period, and the remaining animals were sacrificed with a 5 week recovery period. Examinations for hematology and blood biochemistry were also carried out at the time of recovery period. Based on the results, it was thought that the target tissue or organs were mesothelial cell, injection site, spleen, adrenal gland, ovary and transitional epithelial cell of urinary tract, and no observed toxic level of DWP401 was 0.04 mg/kg while definite toxic dose level might be 0.2 mg/kg.

• Archives of Pharmacal Research
• /
• 제26권8호
• /
• pp.649-652
• /
• 2003

Polymeric nanoparticles composed of polystyrene (PS) as core and poly(methacrylic acid) (PMA) as corona were prepared by the dispersion copolymerization. The potential of the nanoparticles as carriers for recombinant human epidermal growth factor (EGF) was investigated. The nanoparticles showed monodispersity and good water-dispersibility. The loading content of EGF to the nanoparticles was very high due to electrostatic interaction between EGF and nanoparticles. EGF was released as a pseudo-zero order pattern after initial burst effect. The nanoparticles were sufficient for A431 cells proliferation.

• Biotechnology and Bioprocess Engineering:BBE
• /
• 제2권2호
• /
• pp.86-89
• /
• 1997

Epidermal growth factor(EGF) known as a urgastrone is a powerful mitogen with a wide variety of possibilities for medical usages. A mature EGF coding region was isolated from human prepro-EGF sequence by a conventional PCR and cloned into pQE vector in which the gene product was supposed to be expressed with 6$\times$His tag for the subsequent purification. The recombinant mature EGF was expressed in M15[Rep4], an Escherichia coli host strain, in amount of 30-40% of total proteins pressent in E. coli extract by the addition of isopropylthio-$\beta$-galactopyranoside (IPTG). The recombinant EGF purified using a Ni2+-NTA affinity colume chromatography was active in its ability to induce phosphorylation on tyrosine residues of several substrate proteins when murine NH3T3 and human MRC-5 fibroblast cells were stimulated with it. This work may provide the basic technology and information for the production of recombinant EGF.

• Archives of Pharmacal Research
• /
• 제24권4호
• /
• pp.355-359
• /
• 2001

A novel HPLC method with electrochemical detection has been developed for the determination of recombinant human epidermal growth factor (rhEGF) in pharmaceutical products. rhEGF was separated from other components in formulation on a reversed-phase C18 column with 24% acetonitrile in 0.1 M phosphate buffer (pH 4.75). The optimum electrochemical oxidation of EGF was obtained at 0.85 V vs. Ag/AgCl in a glassy carbon working electrode due to electroactive tyrosine, tryptophan, methionine, and arginine residues. The quantitation range was from 1.0 to 200 ng of rhEGF with the linear correlation coefficient greater than 0.999. The method was successfully applied for the quantitation of rhEGF in a pharmaceutical preparation.

• Archives of Pharmacal Research
• /
• 제24권6호
• /
• pp.601-606
• /
• 2001

A simple assay method of recombinant human epidermal growth factor (rhEGF) in a pharmaceutical preparation was studied and validated by capillary electrophoresis (CE) using micellar electrokinetic chromatography (MEKC) techniques. Factors affecting the migration behavior and separation performances of the peptide; type of buffers pH, butler concentration, and concentration of sodium dodecyl sulfates (SDS) were investigated to optimize the analytical performance. CE was performed using running buffers 50.0 mM borate (pH 8.5) containing 12.5 mM SDS at 20 $mutextrm{V}$ of the applied voltage. Calibration curves for the rhEGF showed good linearity (r>0.999) over the wide dynamic range from 1.25 to $100{\mu\textrm{g}}/ml$. Sample analysis was performed by using standard addition method to eliminate the matrix effects of dosage vehicle. This method is assumed to be useful for quality control (QC) of various forms of pharmaceutical products of the peptide.

• 대한의생명과학회지
• /
• 제6권2호
• /
• pp.83-91
• /
• 2000

Protein kinase C는 세포의 신호전달계에 관여하는 중요한 조절효소로서 여러 가지 세포의 분화와 증식과도 밀접한 관련이 있다. 신생아의 포피 keratinocyte를 농도 200 ng/ml의 human recombinant epidermal growth factor (hrEGF)와 human recombinant insulin-like growth factor-1 (hrIGF-1) 그리고 hrEGF와 hrIGF-1의 혼합액을 각각 첨가하여 24시간 배양한후 세포질과 세포막의 PKC단백질을 추출하여 그 농도를 측정하고, Western blot analysis를 이 용하여 각 growth factor들의 PKC isoenzyme에 대한 영향을 분석하였다. 세포질의 총 PKC 단백질의 농도는 hrIGF-1을 처리한 keratinocyte에서 가장 높았으며, 세포막에서는 대조군의 단백질 농도가 가장 높게 나타났다. EGF를 처리한 keratinocyte의 세포질에서 는 PKC-$\beta$II, -$\delta$, -$\theta$가 막성분에서는 PKC-$\alpha$, -$\beta$I, -$\delta$, -$\Im$, -$\theta$가 증가하였다. IGF-1을 처리한 군의 세포질성분에는 PKC-$\beta$I, -$\Im$, -$\theta$, 막성분에서는 PKC-$\alpha$, -$\beta$I, -$\delta$, -$\Im$, -$\varepsilon$, -$\theta$가 증가하였다 EGF와 IGF-1의 혼합처리 군에서는, PKC-$\alpha$, -$\beta$I, -$\Im$, -$\theta$이 세포질에서, PKC-$\alpha$, -$\delta$, -$\Im$, -$\varepsilon$, -$\theta$은 세포막에서 증가하였다.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.1
• /
• pp.299.1-299.1
• /
• 2003

Multivesicular DepoFoam technology is best suited for the encapsulation and sustained release of water-soluble drugs. The purpose of the present study was to prepare multivesicular DepoFoam particles and investigated possibility of oral delivery of a peptide, human epidermal growth factor (rhEGF). The multivesicular DepoFoam particles containing rhEGF was prepared by a two step water-in-oil-in-water double emulsification process. (omitted)

• 한국미생물·생명공학회지
• /
• 제24권4호
• /
• pp.478-484
• /
• 1996

Recombinant human epidermal growth factor (rhEGF) was produced by E. coli BL21 harboring a plasmid pYHB101. The maximum production was 68.7 mg/l when the E. coli strain was cultured at 25$\circ$C for 48 hours in the modified MBL medium containing 10 g/l glucose with 1 mM IPTG induction at 2 hours after inoculation. The rhEGF was purified upto 267 folds by Amberlite XAD- 7 chromatography, ultrafiltration, and DEAE Sepharose fast flow ion exchange chromatography with an overall yield of 66.6%. The purified rhEGF was further separated into two fractions by HPLC. The N-terminal amino acid sequence of the second fraction was Asn-Ser-Asp-Ser-Glu-Cys-Pro-Leu-Ser-His. The effect of rhEGF on the DNA synthesis was examined using in vitro biological assay based on the incorporation of 5'-bromo-2'- deoxy-uridine (BrdU). The purified rhEGF shows no difference with natural human epidermal growth factor (nhEGF) in N-terminal amino acids residues and biological activity. From the results, we concluded that rhEGF produced from E. coli harboring the plasmid pYHB101 was apparently the same as nhEGF.